Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss
Open Access
- 15 August 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (4) , 1078-1085
- https://doi.org/10.1182/blood.v98.4.1078
Abstract
Treatment of cells with the HIV drugs ritonavir, saquinavir, or nelfinavir (Nfv) inhibits apoptosis induced by a variety of stimuli. Because these drugs are protease inhibitors, they have been postulated to inhibit apoptosis by blocking caspase activity. This study shows that Nfv has no effect on caspase activity or on the transcription or synthesis of a variety of apoptosis regulatory molecules. Instead, Nfv inhibits mitochondrial transmembrane potential loss (Δψm) and the subsequent release of apoptotic mediators. Consequently, the antiapoptotic effects of Nfv are restricted to apoptotic pathways that involve Δψm.Keywords
This publication has 67 references indexed in Scilit:
- Decreased HIV-Associated T Cell Apoptosis by HIV Protease InhibitorsAIDS Research and Human Retroviruses, 2000
- Inhibition of Adipocyte Differentiation by HIV Protease InhibitorsJournal of Clinical Endocrinology & Metabolism, 1999
- Protease inhibitors and adipocyte differentiation in cell cultureThe Lancet, 1998
- Improvement in CD4+ Cell Counts despite Persistently Detectable HIV LoadNew England Journal of Medicine, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)The Lancet, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavirBritish Journal of Clinical Pharmacology, 1997
- HIV TherapeuticsScience, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996